Wells Fargo’s Acrivon Therapeutics ACRV Stock Holding History

Wells Fargo’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.17K	Buy	+3,000	New	+$5.23K	﹤0.01%	6160
2025 Q3	–	Sell	-141	Closed	-$168	–	7064
2025 Q2	$168	Sell	141 -6,949	-98%	-$9.54K	﹤0.01%	6450
2025 Q1	$14.4K	Buy	7,090 +157	+2%	+$845	﹤0.01%	5799
2024 Q4	$41.7K	Buy	6,933 +1,511	+28%	+$11K	﹤0.01%	5547
2024 Q3	$38K	Buy	5,422 +231	+4%	+$1.82K	﹤0.01%	5447
2024 Q2	$30.1K	Buy	5,191 +892	+21%	+$7.18K	﹤0.01%	5465
2024 Q1	$30.7K	Buy	4,299 +1,608	+60%	+$7.46K	﹤0.01%	5441
2023 Q4	$13.2K	Buy	2,691 +530	+25%	+$2.8K	﹤0.01%	5754
2023 Q3	$20.7K	Sell	2,161 -1,144	-35%	-$13.2K	﹤0.01%	5584
2023 Q2	$42.8K	Buy	3,305 +1,717	+108%	+$20.8K	﹤0.01%	5488
2023 Q1	$20.2K	Buy	+1,588	New	+$26.7K	﹤0.01%	5635

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's ACRV Position: Q1 2026 in Review

Wells Fargo opened a new position in Acrivon Therapeutics (ACRV) in Q1 2026: 3,000 shares worth $4.17K. The stake represents ﹤0.01% of the portfolio and ranks #6160 among its holdings. This is a return to the name: Wells Fargo previously reported a position in ACRV as recently as Q2 2025.

Wells Fargo first reported a position in ACRV in Q1 2023 and has held it in 11 quarters since. The position peaked at $42.8K in Q2 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Wells Fargo held 3,000 shares of Acrivon Therapeutics worth $4.17K as of Q1 2026.
Acrivon Therapeutics was a new Wells Fargo position in Q1 2026.
Acrivon Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6160 holding.
Wells Fargo first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 11 quarters since.
Wells Fargo's Acrivon Therapeutics position peaked at $42.8K in Q2 2023.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.